Flucloxacillin, a beta-lactam antibiotic of the penicillin class, is considered first line 14 
of these were collected immediately after elastomeric device removal, representing 23 steady-state concentrations, and the remaining 19 were each collected at least 45 24 minutes after device removal to determine clearance of the drug. Plasma 25 concentrations ranged from 13 to 194 mg/L with median steady-state concentration 26 of 51.5mg/L and inter-quartile range of 24.6 mg/L. The time-course of flucloxacillin 27 was best described by a 1-compartment model. The best three covariates, CrCL 28 (ΔOFV= -11.7), eGFR (ΔOFV= -5.9) and serum albumin (ΔOFV= -5.8) were found to 29 information will then provide a rational basis for dosing and determine the 52 requirement for therapeutic drug monitoring in thousands of patients every year. 53 54
Background

56
Flucloxacillin is considered first line therapy for serious methicillin sensitive 57
Staphylococcus aureus in Australia (1) . Being a penicillin derivative, it exhibits "time-58 dependent" bacterial killing and has minimal "post-antibiotic effect" (5). This means 59 that a concentration of flucloxacillin well above the minimum inhibitory concentration 60 (MIC) for the relevant organism will be more effective than a concentration that 61 intermittently falls below the MIC. Intermittent high concentrations will also not 62 compensate for this. Stable concentrations above MIC are best achieved by 63 continuous infusion. Staphylococcus aureus isolates with an MIC >2 mg/L are 64 considered resistant. (6) 65
Our institution has operated a HITH program since 1995 and during that time has 66 administered more than 45,500 days of intravenous flucloxacillin therapy via 67 continuous infusion. The vast majority have received flat dose of 8gram daily. In 68 practice, dose adjustments are only made for children and patients with severe renal 69 impairment (e.g. glomerular filtrate rate (GFR) estimated to be less than 30mL/min. 70
Aims 71
We aimed to describe the PK of continuous flucoxacillin infusion in patients with 72
Staphylococcal infection. Using this PK data, we aimed to develop the simplest 73 possible model of plasma flucloxacillin concentration during HITH that would both 74 inform dosage and quantify inter-individual variation to determine the circumstances 75 TDM is most appropriate. Such a model would potentially take into account the 76 readily measurable quantities of age, sex, weight, height, renal function, and plasma 77 albumin. 78
79
Methods 80
Patients who were enrolled in our facility's 'Hospital-in-the-Home' (HITH) service (the 81 "Out & About" program) and who are receiving flucloxacillin were offered enrolment 82 in our study provided that they were at least 18 years of age and not pregnant or 83 breastfeeding. 84 In some cases, patients were recruited a few days before the Out and About 91 admission when the investigators identified them as suitable candidates. One patient 92 was transferred to a HITH program in another district but was included in the study 93 whilst awaiting transfer as they had already commenced their continuous 94 flucloxacillin infusion in our facility. Patients had weekly assessment by a medical 95 officer along with regular weekly haematological and biochemical parameters 96 monitoring. Our HITH service has a nurse and a physician on call at all times to deal 97 with any immediate problems. 98
Specimen collection for flucloxacillin concentration measurements: 99
Whilst on the Out & About program patient's devices were changed daily. The first 100 blood sample was taken at the time of device disconnection. After at least 45 101 minutes a second blood sample was drawn, and the exact time recorded. All 102 measurements reported in this study used blood collected by peripheral 103
venepuncture. 104
Sample handling and preparation 105
At each time point, 5 ml of blood was collected into an EDTA blood tube. The blood 106 was kept on crushed ice in an insulated container and transferred to the laboratory at 107
Hunter Medical Research Institute (HMRI) by one of the investigators. The samples 108 were centrifuged at 2000 x g for 10 minutes at 4°C. Following this plasma was 109 aspirated from the sample using a sterile pipette. 1ml aliquots in 1ml volumes were 110 placed into appropriately labelled vials. The aliquoted plasma was then stored in a -111 80°C freezer. Bloods were processed within 1 hour of collection. Flucloxacillin was 112 measured using liquid chromatography -mass spectrometry as described in Zhang 113 et al (7). 114
Data Collection 115
The following personal demographic, medical, and physical data were collected after 116 enrolment or on the first study visit and recorded on the Case Record Form (CRF): 117 height, weight, body mass index, date of birth, sex, diagnosis, dosage and duration 118 of flucloxacillin, plasma creatinine and creatinine clearance using Cockcroft-Gault 119 formula, and plasma albumin. 120
PK analysis 121
Flucloxacillin was measured using liquid chromatography -mass spectrometry as 122 described in Zhang et al (7). Briefly, 50 L of sample plus 50 L of Internal Standard 123 was extracted with 400 L acetonitrile. The sample was vortexed and the centrifuged 124 at 15,000 xg for 5min. An aliquot was then transferred to a vial and injected into a 125
Shimadzu 8060 LCMS system. The samples were analysed on a Kinetex C18 2.1 x 126 50mm (1.7m) column with an initial mobile phase of 0.1% formic acid: methanol 127 The published structural pharmacokinetic models for flucloxacillin include 1, 2, and 3 138 compartment models (13,14,15). We considered all these models in our study. 139
Different error models including additive, proportional and combined error models 140 were tested to describe the residual unexplained variability (RUV) of flucloxacillin. 141
Inter-individual variability (IIV) as an exponential relationship was added and tested 142 step-wise for each pharmacokinetic parameter. The off-diagonal elements, 143
representing the covariance of IIVs were tested. Covariates with mechanistic 144 plausibility were tested in this study including gender, age, weight, height, body mass 145 index (BMI), estimated glomerular filtration rate (eGFR), creatinine clearance using 146
Cockcroft-Gault formula (CrCL), and serum albumin. For selection of covariates, a 147 stepwise forward selection followed by backward elimination procedure was applied. 148
The likelihood ratio test was used to discriminate between alternative models. For 149 the forward selection (covariate addition), a decrease in the objective function value 150 (OFV) of 3.84 units (χ 2 , p<0.05) in, was considered statistically significant for one 151 parameter in a nested model. For the backward elimination (covariate subtraction), 152 difference of OFV greater than 10.83 (χ 2 , p<0.001) for deletion from the model was 153 considered statistically significant. Reduction of IIV was also used to assess the 154 influence of covariates. IIV shrinkage was taken into account for precision and bias 155
metrics. 156
Conditional weighted residuals (CWRES) versus time (16), prediction-corrected and 157
variance-corrected visual predictive checks (VPC) (17) were used as diagnostics. 
Patient Characteristics 172
Twenty-three patients (18 males, 5 females) with a median age of 67 were included 173 in this study and 2 of those participated twice ( were sensitive to methicillin/flucloxacillin. Diagnoses included vertebral osteomyelitis 178 (n = 2), bone and joint arthroplasty related infection (n=7), other bone and joint 179 infection except vertebral osteomyelitis and arthroplasty (n 9), and bacteraemia with 180 no deep source (n 5) ( Table 2 ). Organisms were isolated in all 23 patients. No 181 significant haematological and biochemical complications were noted. In particular, 182 no patients developed flucloxacillin-associated neutropenia or hepatitis. 183
Flucloxacillin Dosage 184
One patient received 6g/day of flucloxacillin. All other patients received 8g/day of 185
flucloxacillin. 186
Flucloxacillin concentrations 187
This study utilises flucloxacillin concentrations from 44 separate specimens. 25 of 188 these were steady-state concentrations collected immediately after device removal. The final model parameters were also evaluated with a non-parametric bootstrap, 207 which produced similar parameter values to those in the final model (Table 3) 
(19). 217
Landersdorfer et al used a total daily dose of 6g in healthy volunteers and found that 218 prolonged infusion and continuous infusion both had a 90% probability of producing 219 concentrations above 1mg/L for more than 50% of the time whereas intermittent 220 infusion at the same total daily dose could only do this for concentrations of 0.25 to 221
mg/L or less. (20). For deep-seated infection such as osteoarticular infection 222 or endocarditis, 12 grams/day intermittent dosing is recommended (21). We 223
estimated that the population half-life flucloxacillin to be 49 minutes, allowing 
Limitations 248
This is a single-centre study in which the number of study participants was small and 249 only a limited number of covariates could be evaluated for their effect on population 250 pharmacokinetic parameter estimates. Second, our study is designed to examine the 251 pharmacokinetic properties of flucloxacillin and did not examine clinical outcomes. 252
253
Conclusions 254
Continuous administration of flucloxacillin at dose of 8g over 24 hours using 255 elastomeric devices on a home IV therapy program achieved plasma concentrations 256 of well above five times the MIC for Staphylococci in all cases. CrCL calculated by 257 the Cockgroft-Gault formula was the best predictor of flucloxacillin clearance. 258
Although our study was small, it included patients with CrCL above 250 mL/min. 259
Median volume of distribution was estimated to be 9.5L and flucloxacillin clearance 260 was estimated at 8.1L/hr (Table 3 ) based on population pharmacokinetic modelling 261 which is consistent with studies using intermittent dosing. 262
Clinicians should be comfortable using this method of drug delivery. Consideration 263 can be given to increasing the flucloxacillin dose only in patients with extremely high 264
CrCL>250ml/min). 265 Table 2 . Diagnosis and reason for receiving flucloxacillin.
Diagnosis Number
Infected arthroplasty 7
Vertebral osteomyelitis 2
Other bone or joint infection 9
MSSA bacteraemia alone 5 
